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Abstract: Incidence rates of renal cell cancer, which accounts for 85% of kidney cancers, have 
been rising in the United States and in most European countries for several decades. Family 
history is associated with a two- to four-fold increase in risk, but the major forms of inherited 
predisposition together account for less than 4% of renal cell cancers. Cigarette smoking, obe-
sity, and hypertension are the most consistently established risk factors. Analgesics have not 
been convincingly linked with renal cell cancer risk. A reduced risk of renal cell cancer among 
statin users has been hypothesized but has not been adequately studied. A possible protective 
effect of fruit and vegetable consumption is the only moderately consistently reported dietary 
ﬁ  nding, and, with the exception of a positive association with parity, evidence for a role of 
hormonal or reproductive factors in the etiology of renal cell cancer in humans is limited. 
A recent hypothesis that moderate levels of alcohol consumption may be protective for renal 
cell cancer is not strongly supported by epidemiologic results, which are inconsistent with 
respect to the categories of alcohol consumption and the amount of alcohol intake reportedly 
associated with decreased risk. For occupational factors, the weight of the evidence does not 
provide consistent support for the hypotheses that renal cell cancer may be caused by asbestos, 
gasoline, or trichloroethylene exposure. The established determinants of renal cell cancer, 
cigarette smoking, obesity, and hypertension, account for less than half of these cancers. Novel 
epidemiologic approaches, including evaluation of gene–environment interactions and epigen-
etic mechanisms of inherited and acquired increased risk, are needed to explain the increasing 
incidence of renal cell cancer.
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Descriptive epidemiology
Kidney cancer is the ninth most common cancer in developed countries.1 Approxi-
mately 85% of kidney cancers are renal parenchyma (renal cell) cancers, while the 
remainder for the most part are urothelial cancers of the renal pelvis.2 Approximately 
80% of renal cell cancers are clear cell adenocarcinomas, the remainder being papillary 
(∼15%), chromophobe (∼5%), and collecting duct carcinomas (1%). Both renal cell 
and renal pelvis cancers are about twice as common among men as among women,1–3 
with the mean age at diagnosis in the early 60s for renal cell cancer and in the late 60s 
for renal pelvis cancer. For renal pelvis cancer, there is a strong tendency to develop 
multiple transitional epithelial tumors, particularly in the urinary bladder and ureter.4 
For the most part, renal pelvis cancer parallels bladder cancer in epidemiologic char-
acteristics and risk factors and has been addressed by the authors elsewhere.4
Rates of renal cell cancer vary internationally as much as 10-fold (Table 1), suggest-
ing a strong role for exogenous risk factors in addition to possible roles of geographic 
differences in genetic susceptibility and diagnostic variability. Incidence is generally 
highest in several Western and Eastern European countries, as well as in parts of Italy, 
in North America, and in Australia/New Zealand. The lowest rates are reported in Asia 
and Africa. How much of this difference is a function of completeness of reporting 
by country is not clear, but it probably plays a important role.Clinical Epidemiology 2009:1 34
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Over the past several decades, incidence rates for renal 
cell cancer have been rising steadily each year in Europe and 
the United States,5 although incidence rates appear to have 
recently stabilized or decreased in many European countries.6 
In the United States in 2008, 54,390 new cases and 13,010 
deaths were expected from kidney cancer.2 A recent report 
showed that, while the rate of new cancer diagnoses overall 
dropped 1.8% among men and 0.5% among women in the 
United States between 2001 and 2005, kidney cancer incidence 
rose 1.7% per year for males and 2.2% per year for females.7 
While there has been a decrease in the size of diagnosed renal 
cell tumors over time,8,9 as a result of rapidly improved imag-
ing technology and earlier detection over the last 25 years, an 
increasing incidence of large and late-stage renal cell cancers 
has also been observed and accounts in part for the overall 
increase in incidence.5,9,10 In the United States, increases in 
incidence have been more rapid among women than men11 
and, in particular, among blacks than whites,10 leading to 
a substantial shift in excess from among whites to among 
blacks,10 which is becoming pronounced over time (Figure 
1). Age-adjusted incidence rates of renal cell cancer among 
white men, white women, black men and black women in the 
United States during 2000–2005 were, respectively, 16.31, 
8.03, 19.24, and 8.87 per 100,000 person-years3 (Table 2).
Five-year relative survival rates for renal cell cancer in the 
United States reached 65.1% among men and 66.8% among 
women by 2005,3 compared with below 40% in the early 
1960s10 (Table 3). For localized renal cell cancer cases, the ﬁ  ve-
year relative survival rate is approximately 90%, regardless of 
race or gender.3 In Europe, kidney cancer mortality peaked in 
the early 1990s at 4.8 per 100,000 in men and 2.1 per 100,000 
in women, and then declined to 4.1 and 1.8 per 100,000, respec-
tively, by 2004.6 Despite increasing incidence rates, United 
States kidney cancer mortality rates, which are based on deaths 
from renal cell cancer as well as cancer of the renal pelvis, 
have been remarkably stable over the past 15 years, ﬂ  uctuating 
between 4.1 and 4.3 per 100,000, suggesting a beneﬁ  t of early 
detection and consequent surgical treatment.
Risk factors for renal cell cancer
Epidemiologic studies for consideration in this review were 
identiﬁ  ed through a MEDLINE® search of the literature. For 
the purposes of this review, all papers published through 2008 
were identiﬁ  ed by use of either the term “renal cancer” or 
the term “kidney cancer” together with the term “risk factor” 
or “epidemiology.” Moreover, all review papers addressing 
risk factors for kidney cancer in general or renal cell cancer 
in particular were identiﬁ  ed, and references were examined 
to supplement, if necessary, papers recovered through the 
initial search. Findings of individual studies were evaluated, 
and a qualitative summary of the results is presented herein. 
In the interest of keeping the paper to a reasonable length, 
we have not attempted to cite every paper that we identiﬁ  ed, 
but rather to emphasize those ﬁ  ndings that reﬂ  ect consistency 
in the literature.
Information on risk factors for renal cell cancer was estab-
lished by a large number of case-control studies starting in the 
1980s and supported more recently by cohort studies.12–71 The 
largest case-control study to date, based on 1,732 cases and 
Table 1 International variation in age-adjusted incidence rates (per 
100,000 person-years) for renal cell cancer in selected countries
Country Male Female
Czech Republic 20 10.2
France, Bas-Rhin 15.6 7.3
Iceland 14.8 7.3
Estonia 14.1 7.9
Italy, Florence 13.7 6.6
Slovakia 12.5 5.8
Poland, Warsaw 12.2 5.9
US SEER: black 12.1 6.4
Italy, Venezia 11.7 5
Germany, Saarland 11.4 6.2
Israel, Jews 11.2 6.1
Finland 11 6.2
Poland, Lower Silesia 10.1 5.7
US SEER: white 9.6 4.9
Canada 9.5 5.2
Australia, New South Wales 8.7 4.6
New Zealand 8.6 4.5
France, Isere 8.3 3.9
Netherlands 8.2 4.6
Norway 8 4.6
Scotland 7.9 4.3
Sweden 7.8 4.8
Denmark 7.4 4.1
UK, England 6.7 3.3
Seoul, Korea 4.5 1.9
Japan, Osaka 4.4 1.5
China, Taiwan 3.6 2.6
Columbia, Cali 2.9 2.3
China, Shanghai 2.6 1.5
Israel, non-Jews 2.5 1.9
Zimbabwe 1.1 1.6
Uganda 1 1.1
Note: Data obtained from Parkin and colleagues.1Clinical Epidemiology 2009:1 35
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2,309 controls, was a multicenter collaborative investigation 
conducted in ﬁ  ve countries using a common protocol, ques-
tionnaire, ﬁ  eld procedures, and analytic techniques.34,72–78 
When citing results from this international collaborative 
investigation, only the combined multicenter results will be 
reported, not center-speciﬁ  c ﬁ  ndings.
Genetic susceptibility
Renal cell cancer occurs in both sporadic and hereditary 
forms. Having a ﬁ  rst degree relative with kidney cancer has 
been associated with a two- to four-fold increased risk in 
most studies.79 Hereditary renal cell cancer tends to occur 
earlier in life than sporadic forms of the disease, and often 
involves bilateral, multifocal tumors.80
Although only about 3%–4% of renal cell cancers are 
explained by inherited predisposition,80,81 it is surprising that 
no cancer has as many different types of genetic predisposi-
tion as renal cell cancer.82 Among the rare high-penetrance 
genetic forms of renal cell cancer are von Hippel–Lindau 
(VHL) disease (predisposing to clear cell cancer), hereditary 
papillary carcinoma, hereditary leiomyomatosis and renal cell 
cancer (papillary), Birt–Hogg–Dubé syndrome (mainly chro-
mophobe and oncocytoma), chromosome 3 translocation-
associated (clear cell), tuberous sclerosis (clear cell), and 
a mutated succinate dehydrogenase (SDHB) gene.80,81 In 
contrast, the only hereditary syndrome with known predis-
position to renal pelvis cancer is hereditary nonpolyposis 
colorectal cancer.80 Genetics play a role in renal cell cancer 
beyond clearly inherited susceptibility, as it has been shown 
that the majority of noninherited clear cell carcinomas are 
associated with inactivation of the VHL gene through muta-
tion or promoter hypermethylation.80
Obesity
Renal cell carcinoma is consistently associated with obesity 
in virtually all epidemiologic studies, including recent large 
Table 2 Age-adjusted incidence rates* for renal parenchyma cancer 
by racial/ethnic group and sex according to SEER program, 2000 
through 2005
No. male (Rate) No. female (Rate)
White 26,195 16.31 15,345 8.03
Black 3,115 19.24 1,884 8.87
Asian 1,258 7.80 731 3.67
American Indian 225 12.58 159 7.67
White non-Hispanic 22,947 16.43 13,232 7.96
White Hispanic 3,248 15.81 2,113 8.65
Notes: *Per 100,000 person-years, age-adjusted using 2000 United States standard 
population. Data sourced from SEER Program 17 Registries population, representing 
26% of the United States population.3
Table 3 Five-year relative and cause-speciﬁ  c survival rates* for 
renal parenchyma cancer by race and sex according to SEER 
program for cases diagnosed from 1990 through 2004
% Male % Female
Relative survival
White 65.1 66.8
Black 60.0 65.0
Cause-speciﬁ  c survival
White 67.7 69.6
Black 70.5 71.7
Notes: *Percentage of cases surviving ﬁ  ve years after diagnosis of a ﬁ  rst primary 
cancer in the renal parenchyma. Data sourced from SEER Program 17 Registries 
Population, representing 26% of the United States population.3
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Figure 1 Trends in age-adjusted (2000 United States standard) incidence of renal cell cancer by race and sex, 1973–2005 (Based on SEER data for nine geographic regions of the 
United States: Atlanta, Georgia; Connecticut; Detroit, Michigan; Hawaii; Iowa; New Mexico; San Francisco/Oakland, California; Seattle/Puget Sound, Washington; and Utah).3Clinical Epidemiology 2009:1 36
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prospective studies in the Netherlands, Norway, and the 
United States.59,60,62,65,70,71,78,83–85 Most studies have found an 
association with elevated body mass index (BMI) among 
both men and women, and abdominal obesity, as indicated 
by waist-to-hip ratio,58,65,70,71,85 may play an important role in 
this association, particularly among women. A quantitative 
review of the published literature reported a summary relative 
risk for renal cell cancer of 1.07 per unit increase of BMI.83 
A more recent meta-analysis reported that associations 
with increased BMI were stronger in women than in men; 
summary risk ratios per 5 kg/m2 increase in BMI were 1.24 
(95% conﬁ  dence interval [CI] 1.15–1.34) among men and 
1.34 (95% CI 1.25–1.43) among women.86
Several plausible mechanisms have been suggested for 
the association between obesity and renal cell cancer, but 
the actual mechanism remains speculative. Obesity may 
promote changes in circulating levels of estrogen and other 
steroid hormones, or elevated levels of insulin-like growth 
factor-I (IGF-I), which could in turn contribute to the devel-
opment of renal cell cancer.87–90 Lipid peroxidation, which 
is increased among obese subjects, has been hypothesized 
to be partly responsible for the association of obesity with 
renal cell cancer through the formation of DNA adducts.91 
Other conjectured mechanisms include elevated cholesterol 
level and down-regulation of low-density lipoprotein recep-
tor, lower levels of vitamin D, and increases in adipose 
tissue-derived hormones and cytokines, such as leptin and 
adiponectin.84,92,93
The increasing prevalence of obesity, rapidly becoming 
a worldwide epidemic,93–95 is likely to account in part for the 
rising incidence of renal cell cancer. Recent calculations sug-
gest the proportion of renal cell cancer attributable to being 
overweight and obese could be as high as 40% in the United 
States and Canada and 30% in Europe.83,87,93,96,97
Cigarette smoking
Cigarette smoking is a recognized though moderate cause 
of renal cell cancer.98 A recent meta-analysis99 of data from 
19 case-control studies (8,032 cases and 13,800 controls) and 
ﬁ  ve cohort studies (1,457,754 participants with 1,326 renal cell 
cancer cases) reports statistically signiﬁ  cant relative risks of 
1.5 and 1.2 for male and female smokers, respectively. There 
was a strong dose-dependent increase in risk, up to 2- and 
1.6-fold among heavy (21 or more cigarettes per day) men 
and women smokers, respectively. There was a signiﬁ  cant 
decline in risk in both sexes with years of cessation, with a 
15% to 30% reduction in risk 10 to 15 years after quitting.99 
Approximately 20% to 30% of renal cell cancers among 
men and 10% to 20% among women are estimated to be 
attributable to cigarette smoking.34,100,101
Hypertension and antihypertensive 
medications
The recent increases in renal cell cancer incidence may be 
associated, again in an unknown way, with the increasing 
prevalence of hypertension in the United States, particularly 
among blacks and among women.101,102 While it is difﬁ  cult 
to separate the effects of hypertension or its treatment on 
renal cell cancer risk, as they are highly correlated variables, 
the collective epidemiologic evidence to date suggests that 
it is hypertension itself that is the determinant. Most stud-
ies have reported risks for renal cell cancer associated with 
either recorded blood pressure or reported hypertension 
ranging between 1.2 and 2 or greater,48,51,54–56,62,68,69,72,103–106 
although not all of the studies were able to adjust for the 
effect of antihypertensive medications. Dose-response rela-
tions between measured blood pressure level and renal cell 
cancer risk have been reported,54,56,106 although only one of 
these studies provided data on women and considered the 
effect of antihypertensive medication.106 In that analysis 
of 254,935 men and women in the European Prospective 
Investigation into Cancer and Nutrition (EPIC), the relative 
risks for the highest versus the lowest category of systolic 
(160 vs 120 mmHg) and diastolic (100 vs 80 mmHg) 
blood pressure were 2.48 (95% CI 1.53–4.02) and 2.34 
(95% CI 1.54–3.55), respectively, independent of use of 
antihypertensive medication. A case-control study reported 
that high systolic and diastolic blood pressures were inde-
pendently associated with increased renal cell cancer risk 
in both sexes when analyses were restricted to those who 
never took antihypertensive medication.103 Several55–57,63,106 
cohort studies have demonstrated an increased risk even after 
exclusion of the early years of follow-up, when early stage, 
prediagnostic renal tumors may themselves lead to elevated 
blood pressure. Recent ﬁ  ndings from the Netherlands cohort 
study105 suggest that the association with hypertension may 
be stronger among the small fraction of sporadic renal cell 
cancer patients with von Hippel–Lindau gene mutations, but 
this needs to be conﬁ  rmed in future studies.
Most epidemiologic studies of antihypertensive drugs 
and renal cell cancer risk have found that diuretic use, a 
causal factor candidate in early studies, is not an inde-
pendent risk factor, and adjustment for high blood pres-
sure appears to eliminate any excess risk associated with 
diuretic use.48,62,72,103 In a study of the various classes of 
antihypertensive medications, no particular type or class of Clinical Epidemiology 2009:1 37
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these medications was consistently associated with renal 
cell cancer risk.107
The biologic mechanism for the association between 
high blood pressure and renal cell cancer risk is unknown. 
Among the candidate hypotheses regarding mechanism 
has been hypertension-induced renal injury and metabolic 
or functional changes within the renal tubule induced by 
hypertension increasing susceptibility to carcinogens. It has 
also been speculated that elevated levels of IGF-I or lipid 
peroxidation associated with hypertension, as well as up-reg-
ulation of hypoxia-inducible factors, could contribute to the 
development of renal cell cancer. Contrary to expectation, 
detection bias due to incidental diagnosis during work-ups 
for hypertension was not supported in a study which directly 
evaluated that hypothesis.108
Analgesics
Historically, the causal connection of heavy use and abuse of 
phenacetin-containing analgesics and transitional cell cancers 
of the renal pelvis has long been recognized. Phenacetin’s 
effect on adenocarcinomas of the renal parenchyma, how-
ever, is inconclusive,27,28,109 and it is now impossible to assess 
because phenacetin-containing analgesics have been off the 
market for up to 30 years in most countries and reliable recall 
of past intake is no longer achievable.
Among other analgesics, acetaminophen has received the 
most attention, since it is the major metabolite of phenacetin, 
although several studies have also examined the effect of 
aspirin use on renal cell cancer.21,73,109–113 Neither acetamino-
phen nor aspirin has been credibly associated with an increase 
in renal cell cancer risk.73,111
Statins
Statins are widely used drugs for the treatment of lipid dis-
orders, particularly hypercholesterolemia. Despite reported 
antitumorigenic activity of statins, including their inhibition 
of proliferation and promotion of apoptosis, their potential 
effectiveness for the primary prevention of cancer remains to 
be reliably demonstrated. While some observational studies 
have reported inverse associations with cancer, neither the 
Cholesterol Treatment Trialists’ (CTT) Collaboration114 nor 
two recent meta-analyses115,116 found evidence of an effect 
of statin therapy on cancer risk. A study based on Veteran 
Affair (VA) databases in the United States reported a 50% 
reduced risk of renal cell carcinoma among statin users com-
pared with nonusers.117 This ﬁ  nding may be inﬂ  uenced by 
selection bias, however, since the controls were drawn from 
frequent users of the VA system who might be more likely to 
be prescribed statins. Furthermore, the study did not address 
the inﬂ  uence of dose, duration, and type of statin in relation 
to renal cell cancer risk. There is some evidence that only 
lipophilic statins, such as simvastatin and lovastatin, possess 
antineoplastic effects, whereas hydrophilic statins, such as 
pravastatin, do not have chemopreventive potential.118,119 
Other epidemiological studies reporting on the association 
of statin use and urologic cancers have yielded inconsistent 
results;119–125 however, only combined results for kidney and 
bladder cancer were presented in many of these studies. 
A follow-up study of 361,859 statin users, most of whom 
received lovastatin or simvastatin, found a non-signiﬁ  cantly 
increased risk of kidney/renal pelvis cancer.125 Two case-
control studies reported no association between current or 
regular statin use and kidney cancer.121,123 Most published stud-
ies on statin use had relatively short follow-up and reported for 
the most part only on the most common cancer types. Further 
research is warranted to investigate the association between 
use of statins and any potential increase or decrease in risk of 
renal cell cancer, with particular focus on duration, intensity, 
and type and dose of statin used.
Dietary factors
Renal cell cancer has not been convincingly linked to any 
speciﬁ  c dietary factor, with the exception of a moderately 
consistent protective effect for overall fruit and vegetable 
consumption.61,126–130 However, two recent large prospective 
studies, one based on 375,851 participants in the EPIC 
study131 and the other based on 120,852 men and women in 
the Netherlands Cohort Study on Diet and Cancer (NLCS),132 
reported no protective effect of vegetable and/or fruit con-
sumption on renal cell cancer. Some epidemiologic studies 
suggest that elevated protein consumption may be a risk 
factor for renal cell cancer. There may be some biologic 
plausibility to a high protein diet affecting risk of renal cell 
cancer, because animal studies have shown protein intake 
can induce renal tubular hypertrophy, but the largest study 
to date to evaluate this association failed to provide clear 
support for this hypothesis,78 as has a large, pooled analysis 
of 13 cohort studies.133
Elevated risks have been reported for consumption of 
meat,16,24,27,28,47,128 milk,21,25 and margarine, oils and other fat 
types;25,47 however, most of these ﬁ  ndings were not adjusted 
for confounding by energy intake. Sporadic inverse asso-
ciations have been reported with respect to vitamin C,47 
Vitamin E,78,128 carotenoids,127 and calcium,128 but no particular 
micronutrient or vitamin has been consistently observed to 
decrease or increase the risk of renal cell cancer in case-control Clinical Epidemiology 2009:1 38
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or cohort studies. Although originally thought almost 30 years 
ago to be a key area for renal cell cancer causation, dietary 
studies have not fulﬁ  lled their early promise.
Alcohol consumption
Early ecologic studies consistently suggested a positive cor-
relation between kidney cancer and per capita consumption of 
alcohol.134–136 However, these ecologic ﬁ  ndings were not con-
ﬁ  rmed by numerous analytic epidemiologic studies of renal 
cell cancer conducted during the ensuing two decades.4,66 
After adjustment for the confounding effect of cigarette use, 
virtually all studies showed no association between alcohol 
consumption and renal cell cancer.16–20,24,25,27,28,30,78 Cohort 
studies of alcoholics and brewery workers have also reported 
no excess of mortality from kidney cancer.137–142
By contrast, a post hoc hypothesis has recently appeared 
in the literature that moderate levels of alcohol consump-
tion may be protective for renal cell cancer. The ﬁ  ndings of 
recent individual studies show considerable heterogeneity 
and inconsistency with respect to the categories of alcohol 
consumption, the amount of alcohol intake reportedly asso-
ciated with decreased renal cell cancer risk, and differential 
observations between men and women. A pooled analysis 
of data from 12 prospective studies of renal cell cancer was 
recently published, based on results of ﬁ  ve published stud-
ies58,143–145 as well as numerous others which had not previ-
ously published their data related to alcohol consumption.146 
The pooled analysis was based on 1430 incident cases of renal 
cell cancer (719 men and 711 women), and demonstrated 
an apparent inverse-response relation at levels of consump-
tion equivalent to less than a drink per day, with no further 
protective effect at levels of intake above a drink a day. 
It is difﬁ  cult to speculate what biologic mechanism could 
explain this type of dose-response pattern, unless of course 
one invokes a hormesis-like effect of low-dose alcohol on 
renal cancer risk while other organs seemingly do not enjoy 
this anticarcinogenic effect.
Finally, alcohol itself is a known human carcinogen 
and heavy alcohol drinking has been conclusively linked 
to increased risks of numerous types of cancer, including 
oral, pharyngeal, laryngeal, esophageal, liver and probably 
breast and colon and rectum.147 A protective effect of alcohol 
consumption on renal cell cancer at very low levels of intake 
has little biologic plausibility or face validity. In addition to 
the extensive analytic epidemiologic evidence from the past 
40 years, the descriptive patterns of renal cell carcinoma 
are not consistent with an inverse association with alcohol 
intake. In particular, the rate of renal cell carcinoma among 
men is twice that among women worldwide, whereas men 
tend to consume alcohol at substantially higher levels than 
women.
Hormonal and reproductive factors
Reductions in risk of renal cell cancer have been reported 
among users of oral contraceptives in some,76,148 but not all 
studies,149,150 and in the large international case-control study 
protection was restricted to nonsmokers.76 Several studies 
have reported an almost two-fold increased risk among 
women with high parity compared with nulliparous women, 
after adjustment for obesity,76,148,151 and an inverse associa-
tion between age at ﬁ  rst birth and risk of renal cell cancer 
has been reported in some28,39,149,151 but not all studies.148,150 
Hormones have induced renal tumors in laboratory animals; 
however, with the exception of a positive association with 
parity, evidence for a role of hormonal or reproductive fac-
tors in the etiology of renal cell cancer in humans is limited 
and not entirely consistent to date.
Occupation
As compared with bladder cancer, renal cell cancer has not 
been convincingly linked to any occupational exposure.4 
However, because of the large number of epidemiologic 
studies, particularly case-control studies, that have been 
conducted over the last three decades, a number of spo-
radic associations have been reported between exposures 
or jobs/industries and renal cell cancer. Asbestos has been 
associated with elevated renal cancer mortality in two cohort 
studies, one of insulators152 and one of asbestos products 
workers,153 as has self-reported asbestos exposure in several 
case-control studies, including the large international study.75 
An extensive meta-analysis of occupational cohort studies of 
asbestos-exposed workers showed little relation to increased 
risk for renal cancer.154
In the early 1980s, unleaded gasoline was suspected as 
a risk factor for renal cell cancer based on long-term rodent 
bioassays in which male rats developed renal tumors. Since 
then, a number of occupational cohort and nested case-con-
trol studies have examined the effect of gasoline exposure 
in numerous populations, and the collective evidence to date 
does not support a relation between gasoline and risk of renal 
cell cancer.155–165 Further, the mechanism by which male rats 
developed kidney cancer when exposed to unleaded gasoline 
vapors, via a unique protein molecule, alpha2 microglobulin, 
has no counterpart in humans.156,166
In recent years, considerable attention has focused on 
the solvent trichloroethylene (TCE), largely as a result of Clinical Epidemiology 2009:1 39
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animal ﬁ  ndings and of three epidemiologic studies conducted 
in one area of Germany, initiated in response to a cluster of 
renal cell cancer cases observed in a plant. All three of these 
studies reported strikingly elevated relative risks for renal 
cell cancer associated with TCE exposure.167–169 The ﬁ  nd-
ings contrast starkly with results from other investigations, 
and several serious methodological shortcomings of these 
studies have been noted,170–172 limiting any conclusion that 
can be drawn. To date, seven occupational cohort studies 
have evaluated the relationship between TCE exposure and 
speciﬁ  c types of cancer. The two largest employed sophisti-
cated methods of exposure assessment and both internal and 
external comparisons.173,174 Neither of these studies reported 
a signiﬁ  cantly increased risk of renal cell cancer among 
TCE-exposed workers. The most recent cohort study,175 
conducted in Denmark, evaluated cancer incidence among 
40,049 workers with presumed TCE exposure and found a 
weak association with renal cell cancer among those thought 
to be heavily exposed to TCE. The weight of the evidence 
to date, however, does not provide consistent, credible 
support for the hypothesis that TCE is a cause of renal cell 
cancer in humans.176 Whether TCE is a renal carcinogen in 
humans remains an open question, which will require more 
and better research.
A German study reported that VHL mutations were found 
in 33 of 44 RCC patients from North Rhine–Westphalia with 
TCE exposure.177,178 Of the 33 patients with VHL mutations, 
14 had multiple VHL mutations and remarkably, 13 had the 
same C to T substitution in codon 81.177 Two subsequent stud-
ies could not conﬁ  rm either the tendency towards multiple 
VHL mutations or the VHL codon 81 mutation hot spot in 
TCE-exposed RCC patients from Germany and France.179,180 
In view of the widespread use of TCE around the world, it is 
noteworthy that among approximately 600 VHL mutations 
reported in sporadic RCC patients from other published stud-
ies (predominately of western European patients), only one 
other C to T substitution in codon 81 has been reported.181 
This suggests that the VHL mutation hot spot in the German 
study resulted from either a unique TCE exposure situation 
in a restricted geographic area or some other environmental 
exposure prevalent in that geographic area. If the VHL codon 
81 mutation hot spot is a marker for TCE-induced RCC, then 
the overall ﬁ  ndings suggest that TCE is not a major contribu-
tor to the global RCC burden.
Kidney transplantation and dialysis
Acquired renal cystic disease of the native kidneys is 
believed to account for the substantially higher average 
annual incidence of renal cell carcinoma in dialysis patients, 
independent of patient age or underlying renal disease.182,183 
Several recent studies of cancer risk subsequent to kidney 
transplantation have found a substantially increased risk 
of acquired renal cystic disease and renal cell cancer com-
pared with the general population, presumed to be a result 
of immune-suppressing medications used in transplant 
patients.184
Summary
To date, the causal determinants identiﬁ  ed for renal cell 
cancer in epidemiologic studies, cigarette smoking, obesity, 
and hypertension, are at best moderate in their effect on 
risk and account for less than half of these cancers. Major, 
explanatory causes of renal cell cancer await novel epide-
miologic approaches, including more sophisticated genetic 
studies. Because single-gene determinants of renal cell cancer 
have been thoroughly investigated for almost 30 years with 
at best very limited success, future investigations should 
examine more complex genetic associations, including 
gene-environment interactions and epigenetic mechanisms 
of inherited and acquired increased risk.
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